Product Pipeline

Candidate & Indication Clinical Stage Conducted
Preclinical Phase 1 Phase 2 Phase 3 Market
REM-001 Cutaneous Metastatic Breast Cancer
Preclinical Not Started
Phase 1 Not Started
Phase 2 Not Started
Phase 3 Not Started
Market Not Started
REM-001 Recurrent Basal Cell Carcinoma Nevus Syndrome (BCCNS) and Locally Advanced Basal Cell Carcinoma (laBCC)
Preclinical Not Started
Phase 1 Not Started
Phase 2 Not Started
Phase 3 Not Started
Market Not Started
REM-001 Cutaneous Metastatic Cancers Other than CMBC (e.g., Lung, Ovarian and Colon)
Preclinical Not Started
Phase 1 Not Started
Phase 2 Not Started
Phase 3 Not Started
Market Not Started

Adgero is focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious cutaneous oncology indications. Its lead product candidate, REM-001 Therapy, has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer ("CMBC"), who had previously received chemotherapy and failed radiation therapy. Completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.